Global News

goBalto launches Analyze to advance clinical study start-up reporting

Wednesday, November 19, 2014 02:22 PM

goBalto, a San Francisco-based provider of cloud-based clinical study startup solutions, has released Analyze, a reporting tool that provides a real-time view into clinical operations data.

More... »

IBM Watson Group invests in Pathway Genomics to help personalize consumer health

Wednesday, November 19, 2014 02:15 PM

IBM Watson Group has invested in Pathway Genomics, a San Diego-based clinical laboratory that offers genetic testing services globally, to help deliver the first-ever cognitive consumer-facing app based on genetics from a user's personal makeup.

More... »

Veeva Systems updates Veeva Vault

Wednesday, November 19, 2014 02:13 PM

Veeva Systems, based in Pleasanton, Calif., has released Veeva Vault innovations. Individuals across the organization can share and reuse approved content, eliminating manual hand-offs and duplicate work. At the same time, Vault provides local autonomy and flexibility for each department or region to manage its own content to reflect its unique business processes. Vault maintains one authoritative source document in the cloud to bridge content gaps, increasing efficiency, visibility and compliance. 

More... »

Geron, Janssen collaborate to develop and commercialize imetelstat

Monday, November 17, 2014 02:36 PM

Geron, a Menlo Park, Calif.-based clinical stage biopharmaceutical company, has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies and other human therapeutics uses.

More... »

Boehringer Ingelheim, WellPoint, HealthCore collaborate

Monday, November 17, 2014 02:34 PM

Boehringer Ingelheim Pharmaceuticals (BIPI); WellPoint, an Indiana-based, U.S. health benefit company; and HealthCore, a Wilmington, Del.-based wholly-owned subsidiary of WellPoint, are launching a research project to identify and address unmet medical needs.

More... »

Report: Pharma is improving medicines access, but progress is uneven

Monday, November 17, 2014 02:30 PM

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published by the Access to Medicine Foundation, a nonprofit organization based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries.

More... »

Merck, Pfizer ink alliance on anti-PD-L1

Monday, November 17, 2014 02:28 PM

Merck has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

More... »

Bone Therapeutics, Kasios collaborate on optimization of spinal fusion procedures

Monday, November 17, 2014 02:27 PM

Bone Therapeutics, a Belgium regenerative therapy company addressing unmet medical needs releated to bone diseases and orthopaedics, and Kasios, a French synthetic bone substitute specialist, have announce a two-year collaboration to develop a novel product for spinal fusion procedures. The collaboration combines Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasios's synthetic micro-granules bone substitute. The project is subsidized by the government of the Walloon Region.

More... »

Actavis to acquire Allergan for $66 billion

Monday, November 17, 2014 02:22 PM

Dublin-based Actavis, a global, integrated, specialty pharmaceutical company has announced it will acquire Allergan, a multi-specialty healthcare company based in Irvine, Calif., for approximately $66 billion, or $219 per share.

More... »

Clinical trials not yet paperless

Monday, November 17, 2014 08:00 AM

Typically, when a major shift occurs in how things are managed, there is an adjustment period during which users embrace the new change but are reluctant to let go of some long-standing parts of the old way. 

More... »

CenterWatch Data Library



Browse by:


November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs